| Date/App# |
 List of recent Antibodies-related patents |
07/24/14
20140206853 |  Targeted binding agents directed to dll4 and uses thereof
The invention relates to targeted binding agents against dll4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to dll4. |
07/24/14
20140206849 |  Antibodies having reduced immunogenicity in a human
The disclosure relates to engineered antibodies that when administered to a human, exhibit a low level of immunogenicity in the human. The disclosure also relates to methods for generating the antibodies. |
07/24/14
20140206848 |  Oligosaccharide modification and labeling of proteins
The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.. |
07/24/14
20140206644 |  Methods and compositions for inhibiting cellular proliferation and surgical adhesion
The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. |
07/24/14
20140206579 |  Dna libraries encoding frameworks with synthetic cdr regions
A synthetic dna library or a member of a synthetic dna library of antibodies or fragments of antibody molecules having heavy chain(s) and lacking light chain(s) is described wherein the cdr within variable domains are synthesized using randomly assembled trinucleotide phosphoramidites (trimer phosphoramidites) to eliminate unwanted cysteine amino acids and/or stop codons.. . |
07/24/14
20140206558 |  System for production of antibodies and their derivatives
The present disclosure provides methods and compositions for the production of chimeric antibodies that specifically bind an antigen of interest.. . |
07/24/14
20140206102 |  Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
This document provides methods and materials for detecting c9orf72 hexanucleotide (ggggcc) (seq id no: 3) repeat expansion positive (c9+) frontotemporal lobar degeneration or c9+ amyotrophic lateral sclerosis. For example, methods and materials related to using anti-(gp)8 (seq id no: 2) antibodies to identify mammals (e.g., humans) having c9+ ftld or c9+ als are provided.. |
|
|
07/24/14
20140206099 |  Methods, compositions and kits for labeling of proteins
Provided herein are methods, compositions and kits for labeling of target proteins such as antibodies. The methods, compositions and kits are suited for labeling of such proteins that are mixed with other non-target molecules including bsa, gelatin, and other complex biological molecules.. |
07/24/14
20140206081 |  Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
The present invention relates to the use of variable domains of camelid heavy-chain antibodies (vhh domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns vhh domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.. |
07/24/14
20140206023 |  Methods, kits & antibodies for detecting intact fibroblast growth factor 21
Disclosed are methods, compositions and kits related to immunoassays for detection of fgf21 using antibodies specific to the n-terminal and/or c-terminal of fgf21. The present invention provides antibodies specific to n-terminal or c-terminal peptide of fgf21. |
07/24/14
20140206020 | Voriconazole immunoassays
Methods, compositions and kits are disclosed directed at voriconazole derivatives, immunogens, signal generating moieties, antibodies that bind voriconazole and immunoassays for detection of voriconazole.. . |
07/24/14
20140206018 | Antibodies against fatty acid synthase
The present invention relates to antibodies that immunospecifically bind to fas and certain fas related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. |
07/24/14
20140206004 | Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays
This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. |
07/24/14
20140205656 | Modified cationic liposome adjuvants
The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the igg sub-type response and enhancing the cd8 response of the liposomal adjuvant. This technology can be used to increase the production of igg2 antibodies. |
07/24/14
20140205615 | Human cytomegalovirus neutralizing antibodies and use thereof
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hcmv, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hcmv gene ul products. The invention also relates to immortalized b cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. |
07/24/14
20140205614 | Neutralizing antibodies to influenza viruses
The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza a viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza a virus subtypes, including neutralizing antibodies against two or more of h1, h2, h3, h5, h7 and h9, such as, for example all of h1, h2, h3, and h5 subtypes, and methods and means for making such antibodies. |
07/24/14
20140205612 | Human immunodeficiency virus (hiv)-neutralizing antibodies
The invention provides a method for obtaining a broadly neutralizing antibody (bnab), including screening memory b cell cultures from a donor pbmc sample for neutralization activity against a plurality of hiv-1 species, cloning a memory b cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory b cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the env proteins in native or monomeric form, as well as to inhibit infection of hiv-1 species from a plurality of clades. |
07/24/14
20140205611 | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
Disclosed herein are anti-hgm-csf monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hgm-csf activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. |
07/24/14
20140205607 | Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Antibody vrc01 represents a human immunoglobulin that neutralizes—˜90% of diverse hiv-1 isolates. To understand how such broadly neutralizing hiv-1 antibodies develop and recognize the viral envelope, we used x-ray crystallography and 454 pyrosequencing to characterize additional antibodies from hiv-1-infected individuals. |
07/24/14
20140205606 | Anti c-met antibodies
The present invention relates to antibodies that specifically bind to the human c-met receptor protein and that act as strict antagonists of hepatocyte growth factor (hgf)-mediated activation of the c-met receptor and also inhibit hgf-independent activation of the human c-met protein.. . |
07/24/14
20140205605 | Optimized antibodies that target hm1.24
The present disclosure describes antibodies that target hm1.24. In various aspects, the antibodies have specific cdr, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an fcγr or alters effector function as compared to the parent antibody. |
07/24/14
20140205603 | Siglec-15 antibodies in treating bone loss-related disease
Novel antibodies and antigen binding fragments that specifically binds to siglec-15 are described herein in some embodiments, the antibodies or antigen binding fragments may block the biological activity of siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts the invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.. . |
07/24/14
20140205602 | Antagonist anti-cd40 monoclonal antibodies and methods for their use
Compositions and methods of therapy for treating diseases mediated by stimulation of cd40 signaling on cd40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-cd40 antibody or antigen-binding fragment thereof to a patient in need thereof. |
07/24/14
20140205576 | Methods and compositions for increased transgene expression
Described herein are methods of expressing nucleic acids in t cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-cd3 and anti-cd28 antibodies and the adenoviral vector is pseudotyped for t-cell entry. |
07/24/14
20140205538 | Vaccines targeting cellular death receptors
The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. |
07/17/14
20140201856 | Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. . |
07/17/14
20140201854 | Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. . |
07/17/14
20140200180 | Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins. |
07/17/14
20140200179 | Wnt compositions and methods of use thereof
Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as “mini-wnts”. |
07/17/14
20140200165 | Novel fab fragment libraries and methods for their use
The present invention provides fab libraries and methods for using the fab libraries to obtain antibodies against a target. The fab library of the invention contains at least 109 different fabs, and in some embodiments, at least 1010 different fabs. |
07/17/14
20140200160 | Molecular-based method of cancer diagnosis and prognosis
A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. |
07/17/14
20140200156 | Genes inducing agonistic effects by anti-c-met antibody treatment and drug screening method using the genes
Biomarkers for screening drugs reducing side effects of anti-c-met antibodies and a method of screening using the biomarkers, and more particularly, biomarkers commonly enhancing or reducing gene expression and a method of screening anti-c-met antibodies having reduced side effects using the biomarkers or a method of screening drugs that reduce side effects of anti-c-met antibodies.. . |
07/17/14
20140199763 | Compositions and methods to immunize against hepatitis c virus
Compositions comprising viral antigens and antigenic peptides corresponding to or derived from hepatitis c virus (hcv) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (dcs) are described herein. Included herein are immunostimulatory compositions (hcv vaccines, hcv antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of hcv antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis c in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis c.. |
07/17/14
20140199729 | Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity. |
07/17/14
20140199361 | Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
The invention relates to inhibitory anti-factor xii/fxiia antibodies and methods of their use.. . |
07/17/14
20140199328 | Interferon alpha antibodies and their uses
The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (ifn) alpha subtypes but do not substantially inhibit the biological activity of ifn alpha 21 or the biological activity of either ifn beta or ifn omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. |
07/17/14
20140199323 | Monoclonal antibody
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. |
07/17/14
20140199321 | Stabilizing polypeptides which have been exposed to urea
Methods for stabilizing polypeptides, such as anti-her2 antibodies, which have been exposed to urea.. . |
07/17/14
20140199319 | Methods for increasing the efficiency of hybridoma generation
Disclosed herein are methods for improving the efficiency of the production of hybridomas, e.g., through enrichment of igg expressing b cells. Also disclosed are hybridoma compositions produced using these methods as well as methods for producing antibodies with the hybridomas.. |
07/17/14
20140199318 | Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably alzheimer's disease or vascular dementia.. . |
07/17/14
20140199317 | Actriia binding agents and uses thereof
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to actriia and uses for same.. . |
07/17/14
20140199315 | Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (negative regulator). Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. |
07/17/14
20140199314 | Methods and compositions for regulating iron homeostasis by modulation of bmp-6
Modulation of iron homeostasis by regulating bmp-6 activity is provided. Methods of using bmp-6 and bmp-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. |
07/17/14
20140199313 | Process for the production of fine chemicals
The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use.. |
07/17/14
20140199312 | Ddr1-binding agents and methods of use thereof
The present invention relates to ddr1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of ddr1 and modulate ddr1 activity. |
07/17/14
20140199310 | Compositions comprising agents that inhibit neuropilin and tolloid like 2
We disclose agents that inhibit the expression of neto-2 which has elevated expression in cancer stem cells; the use of neto-2 as a diagnostic or prognostic marker of tumour initiation; the use neto-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind neto-2 and vaccines comprising neto-2 polypeptides.. . |
07/17/14
20140199306 | Compositions and methods for antibodies targeting epo
The present invention relates to compositions and methods for the inhibition of epo. The invention provides antibodies and antigen binding fragments thereof that bind to epo and are able to inhibit epo-dependent cell proliferation and/or epo-dependent cell signaling.. |
07/17/14
20140199301 | Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2/kdr)
Phage displayed recombinant antibody library was developed and the library was screened against vegfr-2. After screening and elisa experiments two recombinant antibodies showing binding properties to vegfr-2 was obtained. |
07/17/14
20140199299 | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target cd3 on t cells and neutralize one or more biological activities of interleukin-6 (il-6), such as cd3 modulators including anti-cd3 antibodies and anti-il-6 antagonists including anti-il-6 antibodies, anti-il-6r antagonists including anti-il-6r antibodies, and/or anti-il-6/il-6r complex antagonists including anti-il-6/il-6r binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.. . |
07/17/14
20140199293 | Humanized antibody compositions and methods for binding lysophosphatidic acid
Compositions and methods for making and using humanized anti-lpa monoclonal antibodies, and fragments and derivatives thereof, are described.. . |
07/17/14
20140199268 | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. |
07/17/14
20140199242 | Compositions and methods for detection and treatment of cancer
Novel antibodies for the detection and/or treatment of a cancer (e.g., a pancreatic cancer or an ovarian cancer) are provided. In certain embodiments the antibodies bind a region of the muc4 protein that does not comprise the central tandem repeat (tr) domain of muc4. |
07/17/14
20140199238 | Targeting of bone marrow neovasculature
Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (aml).. . |
07/17/14
20140199237 | Methods and compositions for modulation of olfml3 mediated angiogenesis
The present invention relates to antibodies against specific domains of olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the olfml3 antagonists.. |
07/10/14
20140196175 | Axmi221z, axmi222z, axmi223z, axmi224z and axmi225z delta-endotoxin genes and methods for their use
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. |
07/10/14
20140194600 | Use of anti-factor xi antibodies for prevention of thrombus formation
The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor xi and that inhibit factor xi activation and/or activity. The factor xi-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor xi activation and/or wherein inhibition of factor xi has a beneficial effect.. |
07/10/14
20140194599 | Anti-human interleukin-20 antibodies
Anti-human il20 monoclonal antibodies that can reduce il20 mediated activation of both il20r1/il20r2 and il22r1/il20r2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.. |
07/10/14
20140194598 | B7-related nucleic acids and polypeptides useful for immunomodulation
The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3. |
07/10/14
20140194351 | Hemipteran-and coleopteran active toxin proteins from bacillus thuringiensis
A novel bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of lygus insects is significantly inhibited by providing the novel crystal protein in lygus insect diet. |
07/10/14
20140194306 | Nucleic acid sequences from diabrotica virgifera virgifera leconte and uses thereof
Expressed sequence tags (ests) isolated from the western corn rootworm, diabrotica virgifera virgifera leconte, are disclosed. The invention encompasses nucleic acid molecules that encode d. |
07/10/14
20140193899 | Monoclonal antibodies to fibroblast growth factor receptor 2
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. . |
07/10/14
20140193855 | Methods and compositions for determining the purity of chemically synthesized nucleic acids
This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.. |
07/10/14
20140193844 | Biomarkers for ankylosing spondylitis
There is described herein methods and peptides for detecting autoantibodies to nog and/or sost in a patient sample in order to diagnose of prognosticate ankylosing spondylitis in the patient.. . |
07/10/14
20140193838 | Method for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies
A method for measuring the amount of sialic acid in immunoglobulin g and immunoglobulin g anti-ds dna antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin g in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin g. |
07/10/14
20140193834 | Blood-brain barrier permeable peptide compositions
Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for alzheimer's disease. |
07/10/14
20140193829 | Monoclonal antibodies against scrapie prion protein
The present invention relates to monoclonal antibodies against prpsc protein. The anti-prpsc mabs produced of this invention can specifically detect prpsc protein from normal mouse brain homogenates without pre-treatment with protease k, which may be used in developing a diagnostic method and kit for prion disease with high specificity and sensitivity.. |
07/10/14
20140193467 | Compositions comprising tnf-specific antibodies for oral delivery
In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. |
07/10/14
20140193462 | Methods for cancer treatment using stem cells
Various embodiments of the invention provide methods of treating cancer. Many embodiments provide methods of treating cancer using stem cells. |
07/10/14
20140193432 | Anti-hdlk-1 antibody having an antitumor activity in vivo
The present invention provides: antibodies specifically reacting against hdlk-1 and having anti-tumor activity in vivo (anti-hdlk-1 antibodies, and in particular, humanized anti-hdlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.. . |
07/10/14
20140193430 | Compositions and methods for regulating nk cell activity
The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of nk cells and allow a potentiation of nk cell cytotoxicity in mammalian subjects. |
07/10/14
20140193429 | Metal-citrate transporter antigen from streptomyces coelicolor and uses thereof
The present invention relates to an isolated antigen from streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. |
07/10/14
20140193428 | Human cytomegalovirus neutralizing antibodies and use thereof
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hcmv, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hcmv gene ul products. The invention also relates to immortalized b cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. |
07/10/14
20140193427 | Anti-gdf15 antibodies
Monoclonal antibodies that bind and inhibit the activity of human gdf15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human gdf15.. |
07/10/14
20140193426 | Markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chemotherapy
The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. |
07/10/14
20140193422 | Fully human antibodies against human 4-1bb
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1bb and that allow binding of human 4-1bb to a human 4-1bb ligand. In one aspect, the antibody is an igg4 antibody. |
07/10/14
20140193421 | Anti-human xcr1 antibodies
An object of the present invention is to provide a monoclonal antibody binding to human xcr1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of seq id no: 91.. . |
07/10/14
20140193418 | Anti-human epo receptor antibodies and methods of use
Herein is reported an antibody that specifically binds to human epo receptor, wherein the antibody binds to epo receptor fragment lpgpggsvdiv (seq id no: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kd.. . |
07/10/14
20140193417 | Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
The present disclosure relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35. |
07/10/14
20140193415 | Bispecific anti-egfr/anti igf-1r antibodies
The present invention relates to bispecific anti-egfr/anti igf-1r antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. . |
07/10/14
20140193414 | Anti-her antibodies
The invention provides anti-her antibodies, including multispecific anti-her antibodies, compositions comprising and methods of using these antibodies. Also provided herein are egfr/her3 multispecific antibodies that are less toxic than traditional egfr antagonists.. |
07/10/14
20140193413 | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (vh) domain and/or a variable light chain (vl) domain, and wherein (a) the vh domain comprises complementarity determining regions (cdrs) selected from the group consisting of: a cdr1 sequence having identity to the sequence of seq id no: 7; a cdr2 sequence having identity to the sequence of seq id no: 8; and a cdr3 sequence having identity to the sequence of seq id no: 9 or 10; and/or (b) the vl domain comprises cdrs selected from the group consisting of: a cdr4 sequence having identity to the sequence of seq id no: 11; a cdr5 sequence having identity to the sequence of seq id no: 12; a cdr6 sequence having identity to the sequence of seq id no: 13.. . |
07/10/14
20140193405 | Humanized anti-cd40 antibodies
Provided are humanized anti-cd40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of cd40 antigen.. . |
07/10/14
20140193404 | Glycosylated antibodies
The invention provides an antibody comprising human igg1 or igg3 heavy chain constant domains that are glycosylated with a sugar chain at asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of ngna is 1% or less and/or the amount of n-terminal alpha 1,3 galactose is 1% or less, and uses thereof.. . |
07/10/14
20140193403 | Epitopes of il-17a and il-17f and antibodies specific thereto
The present invention relates neutralising epitopes of il-17a and il-17f and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.. |
07/10/14
20140193402 | Anti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity. |
07/10/14
20140193401 | Pertussis antibodies and uses thereof
Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.. |
07/10/14
20140193400 | Stable and soluble antibodies inhibiting tnf alpha
The present invention relates to particularly stable and soluble scfv antibodies and fab fragments specific for tnf, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of tnf, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of tnf-mediated disorders. |
07/10/14
20140193399 | Anti-cd3 antibodies and methods of use thereof
The present invention is related to antibodies directed to the antigen cd3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to cd3. |
07/10/14
20140193359 | Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2. |
07/10/14
20140193329 | Anti-cd151 antibodies and their use in the treatment of cancer
The present invention relates to new antibodies capable of binding specifically to the human cd151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the cd151 protein. |